Gaudio, Eugenio <br/><br/>
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.  [electronic resource] 

 -  Oncotarget  Sep 2016 
 - 58142-58147 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.10983  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetanilides--pharmacology<br/>Adenine--analogs & derivatives<br/>Agammaglobulinaemia Tyrosine Kinase<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Cell Line, Tumor<br/>Drug Synergism<br/>Everolimus--pharmacology<br/>Heterocyclic Compounds, 3-Ring--pharmacology<br/>Histone Deacetylase Inhibitors--pharmacology<br/>Humans<br/>Hydroxamic Acids--pharmacology<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Mice<br/>Mice, Inbred NOD<br/>Mice, SCID<br/>Molecular Targeted Therapy--methods<br/>Piperidines<br/>Protein Kinase Inhibitors--pharmacology<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Pyrazoles--pharmacology<br/>Pyrimidines--pharmacology<br/>Rituximab--pharmacology<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Vorinostat<br/>Xenograft Model Antitumor Assays